The current financial score of Roivant Sciences Ltd is 6.30. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.44M, representing a year-over-year decrease of 33.55%, while its net profit experienced a year-over-year decrease of 15.01%.
The current valuation score of Roivant Sciences Ltd is 9.50. Its current P/E ratio is -90.25, which is -102.34% below the recent high of 2.11 and -7.23% above the recent low of -96.78.
The current earnings forecast score of Roivant Sciences Ltd is 8.67. The average price target is 45.61, with a high of 55.00 and a low of 35.78.
The current price momentum score of Roivant Sciences Ltd is 4.81. Currently, the stock price is trading between the resistance level at 43.18 and the support level at 34.11, making it suitable for range-bound swing trading.
The current institutional shareholding score of Roivant Sciences Ltd is 7.00. The latest institutional shareholding proportion is 79.01%, representing a quarter-over-quarter increase of 3.66%. The largest institutional shareholder is Joel Greenblatt, holding a total of 1.35M shares, representing 0.11% of shares outstanding, with 51.64% increase in holdings.
The current risk assessment score of Roivant Sciences Ltd is 7.11. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.